Corticothérapie intratympanique de rattrapage pour les surdités brusques sévères ou profondes - 17/09/14
Résumé |
But de la présentation |
Intratympanic corticosteroids (IT) have been proposed to treat idiopathic sensorineural hearing loss (SNHL). The aim of this study was to evaluate the results of intratympanic steroids as a salvage treatment for severe SNHL in a control group study.
Matériel et méthodes |
A regimen of three IT steroids was offered to patients who failed a 7-days intravenous steroid treatment. Eighty-four patients underwent IT salvage treatment (IT GROUP). Their outcomes were compared with those of 255 control patients with severe SNHL who received the same intravenous steroid regimen without salvage IT steroid therapy (CONTROL GROUP). Types of SNHL were classified into five subgroups according to their audiogram patterns.
Résultats |
The initial pure tone averages (PTA) were 77±29dB and 78±35dB in the IT GROUP and the CONTROL GROUP, respectively (p=0.68). Fifty-six percent of the patients in the IT GROUP had a hearing improvement of>15dB after one month. The average hearing improvements after one month were 26.5±28dB and 27.9±24dB in the IT GROUP and the CONTROL GROUP, respectively (p=0.67). However, for patients with a type E audiogram pattern (total deafness), there was a substantial hearing gain.
Conclusion |
Although intratympanic steroids failed to show a global auditory benefit as a salvage treatment for the whole population of patients with severe SNHL, our data suggest that a salvage treatment with intratympanic dexamethasone may be offered to patients with total deafness for whom the first systemic treatment has failed.
Le texte complet de cet article est disponible en PDF.Plan
Vol 131 - N° 4S
P. A21 - octobre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.